1,246 Doximity (DOCS) shares withheld to cover RSU taxes for interim PFO
Doximity's interim PFO and PAO, Siddharth Sitaram, had 1,246 Class A Common Stock shares withheld by the company to satisfy tax obligations related to vesting Restricted Stock Units (RSUs). This was a mandatory tax-withholding disposition, not a discretionary trade, at a price of $18.01 per share. Following this transaction, Sitaram directly owns 88,150 shares of Doximity.
Doximity (NYSE: DOCS) CEO granted PSUs while shares withheld for tax
Doximity, Inc.'s CEO, Jeffrey Tangney, was granted 322,614 shares of Class A Common Stock as performance-based restricted stock units (PSUs). Simultaneously, 14,964 shares were withheld at $18.01 each to cover tax obligations on previously vested units, which was a mandated non-discretionary action. After these transactions, Tangney directly holds 2,555,424 Class A shares, with future PSU vesting scheduled for May 2026 and May 2028.
Doximity (DOCS) Is Down 27.0% After Softer 2027 Outlook And Higher AI Spend - What's Changed
Doximity (DOCS) recently reported Q4 and full-year fiscal 2026 results, showing revenue growth but declining net income due to profitability pressure. The company's stock fell 27.0% following a softer fiscal 2027 outlook and increased AI-related spending, which sharpens concerns about its investment narrative despite a new AI integration with Aledade. Analysts are now re-evaluating their forecasts, with some already cautious about slower revenue growth and shrinking margins.
Doximity (DOCS) founders report combined stakes equal to 77% voting power
Doximity, Inc. founders Jeffrey Tangney and Claudia Schweikert, along with related trusts, have filed an amendment to their Schedule 13G/A, detailing their beneficial ownership stakes in the company. The filing indicates that Tangney and Schweikert each beneficially own 55,459,800 shares, representing 29.9% of Class A on a conversion basis. Due to Doximity's dual-class share structure where Class B shares carry ten votes each, their combined holdings account for 77.0% of the aggregate voting power.
Stock Market Today: S&P 500, Dow Jones Futures Gain As Trump Clears NVDA's H200 Sales To China—Cisco Systems, Doximity, Grocery Outlet In Focus
U.S. stock futures rose on Thursday, with the S&P 500 and Dow Jones Futures gaining ground amidst President Trump's visit to China and the clearance of Nvidia's H200 AI chip sales to some Chinese firms. Cisco Systems, Doximity, and Grocery Outlet were among the stocks in focus due to significant price movements following earnings reports and guidance updates. Analysts from BlackRock maintained a pro-risk stance on U.S. equities, even as the market navigates ongoing inflationary pressures and rising long-term yields.
These Analysts Slash Their Forecasts On Doximity After Q4 Results
Doximity (NYSE: DOCS) reported mixed fourth-quarter results, beating revenue estimates but missing on adjusted earnings, and provided weak first-quarter and fiscal 2027 sales guidance. Following this, several analysts downgraded the stock or lowered their price targets, despite the company's report of increased user engagement. Doximity's shares dropped significantly in pre-market trading after the announcement.
Doximity interim PFO Siddharth sells $59,502 of class A stock By Investing.com
Sitaram Siddharth, Interim PFO and PAO at Doximity (NYSE:DOCS), sold 2,309 shares of Class A Common Stock for $59,502 on May 11, 2026, as part of a Rule 10b5-1 trading plan and for tax obligations. Simultaneously, he acquired 5,000 Class A shares by converting Class B shares from a stock option exercise. Despite recent stock weakness, InvestingPro analysis suggests Doximity is undervalued with strong financial health, and the company recently reported mixed Q4 earnings but provided strong fiscal 2027 revenue guidance.
Doximity interim PFO Siddharth sells $59,502 of class A stock By Investing.com
Sitaram Siddharth, Interim PFO at Doximity Inc. (NYSE:DOCS), sold 2,309 shares of Class A Common Stock for $59,502 on May 11, 2026, as part of a Rule 10b5-1 trading plan and for tax obligations. Despite this sale and recent stock decline, Siddharth also acquired 5,000 Class A shares through a Class B conversion, now holding 89,396 shares. InvestingPro suggests Doximity is undervalued with "GREAT" financial health, and the company recently exceeded Q4 revenue estimates and provided strong fiscal 2027 guidance.
Doximity Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Doximity, Inc. (NYSE: DOCS) is set to release its fourth-quarter earnings on Wednesday, May 13, with analysts expecting 28 cents per share and $143.91 million in revenue. Ahead of the announcement, several analysts from firms like B of A Securities, Keybanc, Evercore ISI Group, JP Morgan, and Barclays have revised their forecasts, with some maintaining ratings while others downgraded or cut price targets. The company also announced the resignation of its CFO, Anna Bryson, on April 17.
Doximity (DOCS) interim PFO exercises options and sells 2,309 shares under 10b5-1 plan
Doximity's interim PFO and PAO, Siddharth Sitaram, engaged in routine equity transactions, exercising stock options for 5,000 Class B shares, which converted to Class A shares. Concurrently, he sold 2,309 Class A shares at $25.77 each through a pre-planned 10b5-1 "sell-to-cover" transaction to meet tax obligations. This activity is considered neutral as it's a standard tax-related sale and represents a small portion of his overall holdings.
Doximity interim PFO Siddharth sells $59,502 of class A stock
Sitaram Siddharth, Interim Principal Financial Officer at Doximity, sold 2,309 shares of Class A Common Stock worth $59,502 on May 11, 2026, as part of a Rule 10b5-1 trading plan and to cover tax obligations. Simultaneously, he acquired 5,000 Class A shares through the conversion and exercise of a stock option. Despite recent stock weakness, Doximity is considered undervalued with a "GREAT" financial health score, and the company recently reported Q4 earnings that slightly exceeded revenue expectations while providing strong fiscal 2027 guidance.
Doximity interim PFO Siddharth sells $59,502 of class A stock
Doximity's Interim PFO, Sitaram Siddharth, sold 2,309 shares of Class A Common Stock for $59,502 on May 11, 2026, as part of a Rule 10b5-1 plan and to cover tax obligations. Concurrently, he acquired 5,000 Class A shares by converting Class B shares obtained via a stock option. Despite the insider sale and recent stock decline, InvestingPro suggests Doximity is undervalued with a "GREAT" financial health score, and the company recently reported mixed Q4 earnings with revenue beating estimates and provided optimistic fiscal 2027 guidance.
Precision Trading with Doximity Inc. Class A (DOCS) Risk Zones
This article provides a precision trading analysis for Doximity Inc. Class A (DOCS), highlighting strong near and mid-term sentiment despite a weak long-term outlook. It details specific institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses, emphasizing an exceptional risk-reward setup. The analysis also includes multi-timeframe signal analysis for support and resistance levels.
Doximity, Inc. Class A Common Stock (NY: DOCS)
This page provides a news compilation for Doximity, Inc. Class A Common Stock (NYSE: DOCS), featuring various headlines and brief descriptions from June 2023 back to May 2023. The articles cover topics such as Doximity's growth potential, financial performance, analyst ratings, new product announcements, and its role as a network for medical professionals. The stock was listed at $25.98, unchanged, as of 7:00 PM EDT, May 8, 2026.
Doximity director Kira Scherer Wampler sells $234,540 of Class A stock
Doximity director Kira Scherer Wampler sold 9,000 shares of Class A Common Stock for $234,540 on May 7, 2026, following the exercise and conversion of stock options. This sale was conducted via a Rule 10b5-1 trading plan. The transaction occurred amidst a 52% decline in Doximity shares over the past six months, and recent mixed analyst ratings regarding the company's financial outlook and growth prospects.
[Form 4] Doximity, Inc. Insider Trading Activity
Doximity, Inc. director Kira Scherer Wampler sold 9,000 shares of Class A Common Stock at $26.06 per share on May 7, 2026, as part of a pre-planned Rule 10b5-1 trading plan. She also exercised stock options and converted Class B shares to Class A shares. After these transactions, she holds 19,839 Class A shares and 447,700 stock options.
Doximity director Kira Scherer Wampler sells $234,540 of Class A stock
Doximity director Kira Scherer Wampler sold 9,000 shares of Class A Common Stock for $234,540 on May 7, 2026, executing a Rule 10b5-1 trading plan. The sale followed the exercise and conversion of stock options. This transaction leaves Wampler with 19,839 Class A shares and 447,700 stock options, as Doximity shares have recently traded near their 52-week low despite an InvestingPro analysis suggesting they are undervalued.
Is Doximity (DOCS) Turning Physician Network Scale Into a Durable AI Platform Advantage?
Doximity (DOCS) leverages its substantial U.S. physician network and AI-powered tools to maintain a strong position in the digital healthcare market. While its subscription-based, asset-light model provides resilience, the company's future hinges on deepening engagement through AI tools, managing rising compliance costs, and navigating potential shifts in pharma marketing budgets. Analysts project significant revenue and earnings growth by 2029, with a fair value indicating a potential upside.
Doximity CFO Exit Puts Focus On Finance Stability And Capital Choices
Doximity announced the resignation of CFO Anna Bryson, with Chief Accounting Officer Siddharth Sitaram appointed as interim CFO. This leadership change comes as the company's stock, NYSE:DOCS, has seen significant declines over the past year. Investors will be closely watching for stability in the finance team, clarity on the succession plan, and commentary from management regarding the transition, especially with the upcoming fiscal fourth-quarter earnings report on May 13, 2026.
Doximity interim PFO Sitaram sold $51k in DOCS stock
Doximity's Interim Principal Financial Officer, Sitaram Siddharth, sold 2,427 shares of DOCS stock for over $51,000 while also exercising options for 5,000 shares at no cost. This sale occurred as DOCS shares are near their 52-week low. The company has recently seen various analyst updates, with some downgrading due to market conditions and others maintaining positive ratings based on future growth potential and AI tools.
Doximity (NYSE: DOCS) interim PFO sells shares to cover option taxes
Doximity's interim PFO and PAO, Siddharth Sitaram, exercised stock options and converted Class B shares to Class A, then sold a portion of the Class A shares to cover tax obligations. This transaction involved exercising 5,000 shares at $4.12 and selling 2,427 Class A shares at $21.09, all conducted under a pre-arranged Rule 10b5-1 trading plan. Following these actions, Sitaram directly holds 86,705 Class A shares and 78,800 option shares.
Anthropic Managed Agents Test Doximity’s Workflow Moat And Pricing Power
Anthropic's new Managed Agents service, capable of autonomous complex tasks, poses a competitive threat to Doximity's traditional SaaS model in healthcare, potentially challenging its workflow tools and pricing power. Despite Doximity's established HIPAA-compliant network and data, investors are reassessing the company's valuation as advanced AI agents could replicate or compress the value of generic workflow automation. The article explores how Doximity might integrate these agents or face pricing pressure if its offerings are seen as interchangeable with off-the-shelf AI services.
Amazon To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Wednesday
This article compiles the latest analyst rating changes and price target adjustments for ten major companies, including Amazon.com, Inc., Cingulate Inc, and Diamondback Energy Inc. Notably, Cantor Fitzgerald raised Amazon's price target to $260, maintaining an Overweight rating, suggesting a potential 22% rally from its previous closing price. The report highlights a mix of upgrades, downgrades, and target revisions across various sectors.
Doximity, Inc. (DOCS) Stock Price, News, Quote & History
This article provides comprehensive financial information for Doximity, Inc. (DOCS), including its current stock price, recent performance, key financial metrics, earnings trends, and analyst insights. It details the company's business overview as a digital platform for medical professionals and allows for comparison with similar companies in the health information services industry.
Does Doximity’s (DOCS) Scale With Physicians and Cash Flow Redefine Its Healthcare Tech Moat?
Doximity (DOCS) has achieved significant market penetration, reaching over 80% of U.S. physicians, and demonstrating strong financial performance with 29.3% annual revenue growth over five years and robust free cash flow. This success has allowed for a US$500,000,000 share repurchase program and investment in AI tools, reinforcing its position in healthcare technology. However, the company's reliance on pharmaceutical marketing spend remains a key risk, and while analysts project substantial revenue and earnings growth, fair value estimates vary significantly.
Price-Driven Insight from (DOCS) for Rule-Based Strategy
This article provides a price-driven analysis for Doximity Inc. Class A (NASDAQ: DOCS), indicating weak sentiment across all time horizons and supporting a short bias. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes elevated downside risk due to a lack of long-term support signals.
Claim your share of the $31M Doximity securities class action settlement
Investors who purchased Doximity common stock between June 24, 2021, and August 8, 2023, may be eligible for a cash payment from a $31 million securities class action settlement. The lawsuit alleged Doximity and its CEO made misleading statements about active users and engagement levels, leading to inflated stock prices. The claim deadline for this settlement is July 16, 2026.
Vanguard reorganizes reporting; affiliates to report DOCS holdings (DOCS)
The Vanguard Group has amended its Schedule 13G/A filing for Doximity Inc. (DOCS), reporting 0 shares beneficially owned due to an internal realignment on January 12, 2026. This change means that certain Vanguard subsidiaries will now report their beneficial ownership separately, as permitted by SEC Release No. 34-39538. The amendment clarifies that this is a reclassification of reporting responsibility rather than a sale of shares, and the subsidiaries will continue to pursue the same investment strategies.
The Bull Case For Doximity (DOCS) Could Change Following Surge In Physician AI Interest And Concerns
A recent Doximity report indicates that 94% of U.S. physicians are either using or interested in AI, which could significantly alter Doximity's investment outlook. While AI is seen as a way to reduce administrative burdens, 71% of physicians are concerned about its accuracy and reliability. Investors should consider Doximity's reliance on pharma marketing and emerging AI competition, alongside its projected revenue growth and fair value, as these factors will shape its future performance.
A Look At Doximity’s Valuation After New Report On Rapid Physician AI Adoption
Doximity is under scrutiny following a report indicating rapid AI adoption among U.S. physicians, contrasting with a significant decline in its share price over the past year. Despite a perceived 47% intrinsic discount and a narrative suggesting a fair value substantially higher than its current trading price due to expected AI-driven growth, concerns linger about monetization challenges and shifts in pharmaceutical marketing spend. The article suggests investors should independently assess these factors to determine Doximity's true investment potential.
Sitaram Siddharth sells Doximity shares worth $58,833
Sitaram Siddharth, Interim PFO and PAO of Doximity Inc. (NASDAQ:DOCS), sold 2,319 Class A Common Stock shares for $58,833 on March 10, 2026, executed via a Rule 10b5-1 plan, while the stock trades near its 52-week low. Simultaneously, Siddharth converted and acquired 5,000 shares each of Class B stock to Class A and through stock option exercises. This transaction follows Doximity's positive fiscal third-quarter results, although analysts offer mixed perspectives on the company's future due to varying market reactions and marketing budget delays.
Doximity (DOCS) interim PFO exercises options, converts B to A, sells stock
Doximity, Inc.'s interim PFO and PAO, Siddharth Sitaram, exercised stock options for 5,000 shares at $4.12 per share and converted Class B shares to Class A. He subsequently sold 2,282 Class A shares at $27.88 each to cover tax withholding, as part of a Rule 10b5-1 trading plan. Following these transactions, Sitaram directly holds 81,451 Class A Common Stock shares.
Doximity (DOCS) interim PFO exercises 5,000 options, sell-to-cover 2,319 shares
Doximity, Inc.'s interim PFO and PAO, Siddharth Sitaram, exercised stock options for 5,000 shares of Class B Common Stock, converting them to Class A Common Stock. He then sold 2,319 Class A shares at $25.37 each in a pre-planned sell-to-cover transaction to satisfy tax withholding obligations. Following these transactions, Sitaram directly holds 84,132 shares of Class A Common Stock.
Doximity interim PFO Sitaram sells $63,622 in shares By Investing.com
Doximity's Interim Principal Financial Officer, Sitaram Siddharth, sold 2,282 shares of Class A Common Stock for $63,622 while also converting Class B shares and exercising stock options. This transaction occurred as the stock trades near its 52-week low, despite InvestingPro analysis suggesting it is undervalued with an impressive gross profit margin. Analysts have offered varied perspectives on Doximity following strong fiscal third-quarter results, with some lowering price targets due to near-term headwinds and others upgrading the stock based on its AI tool suite and perceived overreactions to market concerns.
Sitaram Siddharth sells Doximity shares worth $58,833
Sitaram Siddharth, Interim PFO and PAO of Doximity Inc., sold 2,319 shares of Class A Common Stock for $58,833 on March 10, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurred while Doximity shares were trading near their 52-week low. The company recently reported better-than-expected fiscal third-quarter results, although analyst ratings and price targets show mixed perspectives due to factors like valuation, AI tool suite assessment, and pharmaceutical marketing budget delays.
Doximity interim PFO Sitaram sells $63,622 in shares
Doximity Interim Principal Financial Officer, Sitaram Siddharth, sold 2,282 shares of Class A Common Stock for $63,622 on February 10, 2026, through a Rule 10b5-1 trading plan. This sale occurred while the stock was trading near its 52-week low, despite InvestingPro analysis suggesting it is undervalued. Recent analyst reports show mixed perspectives, with some price target adjustments due to factors like pharmaceutical marketing delays and AI tool assessments.
Doximity interim PFO Sitaram sells $63,622 in shares
Doximity's interim Principal Financial Officer, Sitaram Siddharth, sold 2,282 shares of Class A Common Stock for $63,622 on February 10, 2026, as part of a Rule 10b5-1 trading plan. Despite the stock's recent decline, InvestingPro analysis suggests it is undervalued, boasting an 89.75% gross profit margin and a P/E ratio of 20.51. This transaction follows varied analyst updates, with some lowering price targets due to near-term headwinds while others upgraded the stock or raised price targets based on strong earnings and AI tool suite potential.
What Analysts Are Saying About Doximity Stock
Over the past three months, 17 analysts have evaluated Doximity (NYSE: DOCS), presenting a range of outlooks with an average 12-month price target of $44.41, a significant decrease from the previous average of $58.65. While some analysts maintained or raised their ratings, a majority lowered their price targets, despite Doximity showing strong financial performance with high market capitalization, positive revenue growth, and impressive net margins, ROE, and ROA.
Doximity (NYSE: DOCS) director trades options and sells 2,000 shares
A Doximity (NYSE: DOCS) director, Kira Scherer Wampler, executed a stock option for 2,000 shares, converted 2,000 Class B Common Stock shares to Class A, and subsequently sold 2,000 Class A shares at $26.00 per share. These transactions, which occurred on March 3, 2026, were part of a pre-scheduled Rule 10b5-1 trading plan adopted in November 2024. Following these actions, her direct Class A holdings decreased to 19,839 shares.
Assessing Doximity (DOCS) Valuation As Positive Analyst Sentiment Builds Around Its Telehealth Platform
This article analyzes Doximity (DOCS) ahead of its ViVE 2026 conference appearance, focusing on its telehealth platform and digital tools. Despite recent stock weakness, the company is seen as significantly undervalued by analysts, trading at a 43% intrinsic discount and over 50% below target prices. The narrative suggests that AI-powered workflow tools will drive platform usage and revenue growth, making it a potential investment opportunity.
Is Doximity’s (DOCS) ViVE 2026 Pitch a Clue to Its Telehealth Moat?
Doximity (DOCS) recently presented at the ViVE 2026 conference, highlighting its digital healthcare tools and platform capabilities for medical professionals. The article discusses Doximity's investment narrative, including its revenue and earnings forecasts which suggest a significant upside to its current price, while also acknowledging risks such as rising competition and regulatory uncertainty. The company also authorized a US$500 million share repurchase, which may influence near-term per-share metrics.
DOCS SEC Filings - Doximity Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Doximity Inc. (DOCS) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It details how Doximity reports financial conditions and governance matters, offering analyses of non-GAAP measures and executive transactions. The page also features AI-powered summaries of filings, recent insider trading activities, and key stock data for DOCS.
Doximity CEO ViVE 2026 Talk Puts AI And Pharma Story In Focus
Doximity CEO Jeffrey A. Tangney will speak at the ViVE 2026 conference, highlighting the company's focus on AI-powered workflow tools, pharma relationships, and health system adoption. This event is crucial for investors to gauge Doximity's platform centrality and monetization strategies for AI, especially given its reliance on pharma marketing budgets. Investors should monitor for insights into AI monetization, competition, and leadership consistency with prior messaging.
Doximity’s $31 Million Investor Settlement Clears Initial Hurdle
A federal court has given preliminary approval for Doximity Inc.'s $31 million settlement with investors in a proposed securities class action lawsuit. The lawsuit alleged that Doximity misled investors about its professional social network's metrics, claiming that over 80% of US physicians used its platform. A hearing for final approval is scheduled for June in the US District Court for the Northern District of California.
Doximity Expands AI Tools As Investors Weigh Profit Strength And Growth
Doximity (NYSE: DOCS) is launching new AI tools, including DoxGPT, to enhance its offerings for medical professionals and deepen its role in doctors' workflows. Despite recent share price declines in a challenging digital health sector, the company maintains strong fundamentals and high profit margins. The success of these new AI features in increasing clinician engagement and monetization will be a key factor for investors to watch, especially given competition and reliance on pharmaceutical marketing budgets.
(DOCS) Risk Channels and Responsive Allocation
This article provides an AI-generated analysis of Doximity Inc. Class A (NASDAQ: DOCS), suggesting a near-term neutral sentiment that might pause its mid and long-term weakness. It identifies elevated downside risk due to a lack of long-term support signals and outlines three institutional trading strategies tailored to different risk profiles. The analysis also includes multi-timeframe signal data and emphasizes real-time signal access.
Doximity (DOCS) CEO logs 8,243-share tax-withholding disposition
Doximity, Inc. CEO Jeffrey Tangney reported a tax-related disposition of 8,243 Class A Common Shares on February 15, 2026. These shares were withheld by Doximity to cover tax obligations arising from the vesting of restricted stock units, explicitly noted as a mandated tax-withholding disposition rather than a discretionary market trade. Following this transaction, Tangney directly holds 2,232,810 shares of Doximity Class A Common Stock.
Doximity Inc. (NYSE:DOCS) Fits the "Affordable Growth" Investment Strategy
Doximity Inc. (NYSE:DOCS) is presented as a strong candidate for an "Affordable Growth" investment strategy, characterized by high profitability, robust financial health, and a track record of growth at a reasonable valuation. The company boasts top ChartMill scores for profitability and financial health, with high margins and no debt. While past growth rates have been exceptional, future projections remain positive, and its current valuation is considered fair compared to industry peers and the broader market.
Doximity (DOCS) Is Down 9.8% After New AI Spend, Buyback Plan And Guidance Update – Has The Bull Case Changed?
Doximity (DOCS) reported mixed Q3 2025 results, with increased sales and updated full-year guidance, but a dip in quarterly profit per share due to delayed pharmaceutical budgets and higher AI infrastructure spending. The company authorized a new $500 million share repurchase program. The article explores how this new guidance and AI investment affect Doximity's investment narrative, highlighting the tension between short-term profitability and long-term product investment, and the continued reliance on pharma marketing exposure as both a catalyst and a risk.
(DOCS) Movement as an Input in Quant Signal Sets
This article analyzes Doximity Inc. Class A (NASDAQ: DOCS) through quantitative signals, indicating weak sentiment across all time horizons and supporting a short bias. It outlines institutional trading strategies including long, momentum breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels. The piece emphasizes elevated downside risk due to a lack of long-term support signals.
